Eris Lifesciences shares gain 4% on partnering with Natco Pharma to launch semaglutide in India

As of 1:25 pm, the stock was trading 1.67% higher at ₹1,375.30 per equity share.

The share has gained 3% in the past week but lost 1% over the month. On a year-to-date basis, it has declined 8%.

While the scrip hit a 52-week high of ₹1,910 per unit on June 12, 2025, it touched a year’s low of ₹1,097.20 on April 7, 2025.

In a regulatory filing, the drug maker said that it has entered into a strategic partnership with Natco Pharma Limited for the commercialisation of Semaglutide.

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction.

Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market. With this regulatory milestone, the drug is expected to launch in March 2026.

“The product will target Type 2 diabetes management, aligning with unmet needs in India’s expanding metabolic care landscape,” Eris Lifesciences said.

According to the statement, the collaboration builds on Eris’s robust commercial and diabetes franchise presence and Natco’s manufacturing and regulatory strengths in complex formulation.

Commenting on the development, Amit Bakshi, Chairman & Managing Director, Eris Lifesciences, said: “Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies, we believe Eris is well-positioned to drive rapid adoption and enhance patient access in India.”

Bakshi further added that Eris has been proactively preparing its commercial strategy to participate meaningfully in the GLP-1 opportunity and views this partnership as a long-term value driver for the company.

Eris Lifesciences Q3 results

The pharmaceutical company posted a 19% year-on-year (YoY) growth in its net profit to ₹99.7 crore for the third quarter of FY26, compared to ₹83.7 crore in the year-ago period.

Its revenue from operations stood at ₹807 crore for the reporting quarter, marking a 10% YoY increase from ₹732 crore in the December FY26 quarter.

Eris Lifesciences has a total market capitalisation of ₹18,739.36 crore, as of February 24, 2026, according to data on the NSE.